#Targeted Nanomedicine For Breast Cancer Therapy PDF
Download full Targeted Nanomedicine For Breast Cancer Therapy Book or read online anytime anywhere, Available in PDF, ePub and Kindle. Click Get Books and find your favorite books in the online library. Create free account to access unlimited books, fast download and ads free! We cannot guarantee that book is in the library. READ as many books as you like (Personal use).
Synopsis : Targeted Nanomedicine for Breast Cancer Therapy written by Shivani Rai Paliwal, published by Academic Press which was released on 2022-07-15. Download Targeted Nanomedicine for Breast Cancer Therapy Books now! Available in PDF, EPUB, Mobi Format. Worldwide, breast cancer is the most common cancer in women, however, breast cancer therapy is always challenging. This book aims to help researchers remain updated on the most targeted nanomedicine research available. -- Targeted Nanomedicine for Breast Cancer Therapy provides a compilation of treatment approaches for breast cancer, including conventional receptor targeting methods and novel strategies like stimuli responsive methods and tumor micro-environment responsive strategies. This book compiles the most important information on the state-of-the-art therapeutics, including breast cancer biomarkers and design principles of bio-responsive nanosystems. Presented in two parts, sections cover basic and receptor mediated targeting approaches and examine tumor microenvironment mediated approaches. This is a useful book for pharmaceutical scientists and basic and clinical scientists working in the research area of breast cancer and drug discovery both from academics and industry. Worldwide, breast cancer is the most common cancer in women, however, breast cancer therapy is always challenging. This book aims to help researchers remain updated on the most targeted nanomedicine research available. Highlights promising breast cancer targets to help design nanomedicines and stimuli-triggered methods for cancer imaging and treatments Provides in-depth exploration of targeted breast cancer therapy, along with highlights to quickly understand the most important points Explores cutting-edge research in the area of targeted nanomedicine and drug delivery, including nanotheranostics for breast cancer therapy
Type: BOOK - Published: 2022-07-15 - Publisher: Academic Press
Targeted Nanomedicine for Breast Cancer Therapy provides a compilation of treatment approaches for breast cancer, including conventional receptor targeting methods and novel strategies like stimuli responsive methods and tumor micro-environment responsive strategies. This book compiles the most important information on the state-of-the-art therapeutics, including breast cancer biomarkers and design principles of bio-responsive nanosystems. Presented in two parts, sections cover basic and receptor mediated targeting approaches and examine tumor microenvironment mediated approaches. This is a useful book for pharmaceutical scientists and basic and clinical scientists working in the research area of breast cancer and drug discovery both from academics and industry. Worldwide, breast cancer is the most common cancer in women, however, breast cancer therapy is always challenging. This book aims to help researchers remain updated on the most targeted nanomedicine research available. Highlights promising breast cancer targets to help design nanomedicines and stimuli-triggered methods for cancer imaging and treatments Provides in-depth exploration of targeted breast cancer therapy, along with highlights to quickly understand the most important points Explores cutting-edge research in the area of targeted nanomedicine and drug delivery, including nanotheranostics for breast cancer therapy
Authors: Arshi Malik, Sarah Afaq, Mohammed Tarique
Type: BOOK - Published: 2021-08-01 - Publisher: Springer Nature
This book reviews the current applications and future prospects of nanomaterials in cancer diagnostics and therapy. Nanomaterials have recently emerged as a remarkable and promising tool for cancer therapy and diagnosis, due to their broad range of intrinsic molecular properties. To overcome the current limitations of nanoparticles in drug delivery systems, attempts have been made to synthesize nanoparticles from biological materials for targeted cancer therapy. This book provides concise evaluations of various potential bio-inspired platforms that mimic natural components of the body and offer effective and versatile drug delivery systems for cancer therapy. It also assesses the potential of nanoparticles to enhance the outcomes of cancer immunotherapy via immune cell activation and tumor microenvironment modulation. The book also summarizes in the applications of nanomaterials for the detection, prevention, and treatment of solid tumors and in the treatment of leukemia and lymphomas. In closing, it discusses ethical issues in nanomedicine, including risk assessment, risk management, and risk communication during clinical trials. The book offers offers a valuable source of information for students, academics, researchers, scientists, clinicians, and healthcare professionals working in nanotechnology and cancer research.
Type: BOOK - Published: 2021-02-04 - Publisher: Springer Nature
The book covers the latest developments in biologically-inspired and derived nanomedicine for cancer therapy. The purpose of the book is to illustrate the significance of naturally-mimicking systems for enhancing the dose delivered to the tumor, to improve stability, and prolong the circulation time. Moreover, readers are presented with advanced materials such as adjuvants for immunostimulation in cancer vaccines. The book also provides a comprehensive overview of the current status of academic research. This is an ideal book for students, researchers, and professors working in nanotechnology, cancer, targeted drug delivery, controlled drug release, materials science, and biomaterials as well as companies developing cancer immunotherapy.
Type: BOOK - Published: 2020-03-08 - Publisher: Elsevier
Nanomedicines for Breast Cancer Theranostics addresses the translational aspects and clinical perspectives of breast cancer nanomedicine from a multidisciplinary perspective. The book summarizes research efforts at the preclinical and clinical stage of nanostructures and nanomedicine for dealing with the important challenge of nanomedicine translation in breast cancer theranostics. This book is an important resource for those working in both academia and industry, focusing on hot topics in biomaterials, biomedical engineering, drug delivery and oncology. Shows how the discovery of new nanomedicines is leading directly to an increase in the early-stage diagnosis of breast cancer Includes coverage of breast cancer nanomedicine standardization and characterization, highlighting newly developed treatments, diagnostics and treatment monitoring tools Explains why the design of nanobiomaterials make them effective drug carriers when treating breast cancer
"Cancer therapy in the recent years has evolved with the development of novel targeted drug delivery systems. The conventional chemotherapy approach is plagued by side effects and numerous disadvantages such as low bioavailability, poor solubility of drugs, toxicity, non-specific drug action and so forth. With the main goal of producing a drug delivery vehicle that is optimally designed to address the many limitations associated with the conventional chemotherapy, the work has been designed as follows: Different lipid-based targeted formulations were prepared, such as the tumor-targeting micelles and liposomes, and the in vitro effects of the formulations on pancreatic and breast cancer cells have been studied to determine their optimal therapeutic effects and their ability to minimize adverse off-target effects. Keeping in mind the need for an ideal therapy requirement for life threatening illnesses, hard to treat pancreatic cancer and the very commonly diagnosed cancer among women, breast cancer, were chosen as the targets for testing designed nano-preparations. The first approach was to develop polymeric micelles self-assembled with a single drug, paclitaxel and a targeting agent, a peptide sequence derived from phage coat protein. The drug is hydrophobic and poorly soluble in aqueous solvents that limit its pharmaceutical applications despite high efficacy. Cell viability studies on PANC-1 pancreatic cancer cells using the targeted phage micelle preparation produced significantly higher cell death of ~45 % while the non-targeted preparation caused only about ~30% cell death at 750ng/ml concentration of paclitaxel. Significantly higher cell death was observed at 1.5 and 2.75 mg/ml concentrations of paclitaxel-loaded in the formulation, that was dose and time dependent. More than a 30% increase in caspase3/7 activity was observed in vitro in a monolayer of PANC-1 cells while the in vivo data on lactate dehydrogenase release indicated a significantly enhanced apoptosis in the PANC-1 spheroid model upon treatment with the targeted micelle preparation. The second approach utilized liposomes modified with monoclonal antibody 2C5 (mAb 2C5) as targeting ligand for breast cancer therapy. The study is important in that a combination of 2 drugs, paclitaxel, a microtubule inhibitor, and salinomycin, an anti-cancer stem cell targeting agent, has been used. The main goal with the use of combination chemotherapeutics was to eliminate not just the bulk cancer cells as with conventional chemotherapy, but also the cancer stem cells, or the tumor-initiating cells, in the core of the tumor to eliminate possibilities of cancer metastasis and recurrence. The study produced promising results for cellular interaction, uptake and cytotoxicity in vitro as was observed both quantitively and qualitatively. Interaction of the mAb 2C5-targeted liposomes was greater than ~3.25-fold with SK-BR-3 breast cancer cells, while the same formulation showed over a ~1.3-fold increase in interaction with the MDA-MB-231 breast cancer cells in comparison to the other controls used. A significantly enhanced fluorescence signal upon treatment of both the breast cancer cells with rhodamine-labeled mAb 2C5-targeted liposomes was observed in comparison to the unmodified liposomes that supported cellular specificity and enhanced cellular uptake of the antibody-targeted formulation. The average of the corrected total cell fluorescence (CTCF) plotted for the mAb 2C5-modified liposome-treated cells from three different locations on the fluorescence image was statistically significant (p £ 0.05) in comparison to that of the unmodified liposome-treated cells in both the cell lines. There was a ~4.5-fold and a ~3.0-fold increase in average CTCF with the mAb 2C5-modified liposomes in comparison to the unmodified liposomes in SK-BR-3 and MDA-MB-231 cells respectively. The quantitative data was a further confirmation for the enhanced cellular uptake of the formulations in both the cell lines. Holographic monitoring confirmed improved cellular killing by showing visible differences in cellular morphology, cell division and proliferation over time (48 hours) that validated the efficacy of the mAb-targeted liposomal formulation in MDA-MB-231 cancer cells. The study also confirmed the specificity of mAb 2C5 for two different breast cancer cell types viz, the triple negative MDA-MB-231 cells and Her2-positive SK-BR-3 cells. Also, preliminary data on hemolysis (%) in female athymic nude mice confirmed lower toxicity for the antibody-targeted combination drug-loaded liposomal formulation in vivo in comparison to the single drug-loaded targeted formulations. Transitioning from the studies using targeted polymeric micelles for pancreatic cancer therapy to mAb-targeted liposomes for breast cancer combination drug therapy, additional studies to demonstrate the stem cell-like properties of the cancer cells were performed. In order to also confirm the potential of the combination therapeutics for breast cancer, in vitro studies were performed using free drugs on a monolayer of breast cancer cells. A cell viability study using free drugs and the study of effects of free drugs (both single drugs and in combination) on cellular morphology and metastasis were performed to demonstrate efficacy of the combination therapeutics on breast cancer cells. Lipodox in combination with salinomycin and paclitaxel in combination with salinomycin were used to treat breast cancer cells in vitro. In comparison to Lipodox alone, the combination therapy showed significantly improved cellular killing over time and with different doses and produced about 50% more cellular killing at 72 hours in MDA-MB-231 cells. In comparison to salinomycin alone, the combination killed about 70% cells in 72 hours. MCF-7 cells were more sensitive to the therapy with lower dose of Lipodox giving enhanced cell killing in combination with salinomycin and achieving significantly higher cell killing percentages at 48 hours and 72 hours after treatment. Significantly improved cell killing percentages were observed with both the cell lines in presence of the combination of drugs as opposed to single agents in a dose and time dependent manner. Characterization of the breast cancer cell lines for presence of cancer stem cell specific markers CD44+/CD24- showed enriched populations of cells expressing these biomarkers over several generations in both the cell lines. Also, unique properties of stem cells such as their differentiation potential and self-renewal properties were demonstrated using the breast cancer cells to successfully confirm the presence of stem cells and to validate the mammospheres generated for their stem cell-like properties. Although the regular expression of CD44+/CD24- marker is variable in different types of breast cancer, the mammospheres generated in MCF-7 cells showed high levels of CD44+/CD24- expression (that is different from the usual expression profile of CD44, CD24 in such basal/ epithelial breast cancer cells) validating the enrichment of cells with stem cell-like properties over generations using the 3D mammosphere culture system. The MDA-MB-231 cancer cells with intrinsically higher expression of CD44+/CD24- marker (as expected with the basal/mesenchymal cancer cells) showed consistent high expression of the marker in the various generations of the cancer cells in the mammospheres. The results also highlighted the biological heterogeneity of different types of breast cancers. Additional holographic studies on wound healing of a monolayer of breast cancer cells revealed that the combination of free drugs (salinomycin and paclitaxel) treatment of wounds on a monolayer of MDA-MB-231 cells showed a reduction in gap width at the wound site from ~355um at the beginning of holographic monitoring to only ~219um at the end of the wound healing assay in comparison to a reduction to ~7um with salinomycin-only and to ~104um with paclitaxel-only treated wounds. The ability of the combination chemotherapy to prevent cellular migration at the wound suggested its potential to inhibit cellular proliferation and metastasis in vivo. Overall, the study below is valuable for the development of targeted drug delivery systems for pancreatic and breast cancer therapy. We hope that the work translates in the clinic and provides an optimal outcome in people with this life-threatening malady"--Author's abstract.
Authors: Deepak Chitkara, Anupama Mittal, Ram I. Mahato
Type: BOOK - Published: 2018-09-03 - Publisher: CRC Press
The field of molecular medicine covers the medical interventions targeting molecular structures and mechanisms that are involved in disease progression. In cancer, several molecular mechanisms have been shown to impact its progression, aggressiveness and chemoresistance. Increasing evidence demonstrates the role of nanotechnology and outcome of molecular therapy. Several books have discussed molecular biology and mechanisms involved in cancer, but this text gives an account of molecular therapeutics in cancer relating to advancements of nanotechnology. It provides a description of the multidisciplinary field of molecular medicines and its targeted delivery to cancer using nanotechnology. Key Features: Provides current information in the multidisciplinary field of molecular medicines and its targeted delivery to cancer using nanotechnology Presents important aspects of nanotechnology in the site-specific delivery of anticancer agents Includes up to date information on oligonucleotide and gene based therapies in cancer Describes small targeted molecules, antibodies and oligonucleotides which have shown to selectively target the molecular structures thereby influencing signal transduction Facilitates discussion between researchers involved in cancer therapy and nanoscientists
Type: BOOK - Published: 2019-04-03 - Publisher: Frontiers Media SA
Since the invention of nanomedicine decades ago, considerable progresses have been made, especially with cancer as a target. Nanoparticles have been proven to be powerful imaging tools or potent agents for cancer diagnosis, treatment and prevention. Active research spread from fundamental research to clinical investigations. This topic intends to cover several important aspects in this field including nanocarrier development, gene delivery, intrinsically active nanoparticles, tumor microenvironment, immunology, and toxicity.
Type: BOOK - Published: 2020-02-19 - Publisher: CRC Press
In recent years, nanoparticles—bionanomaterials with specific physicochemical properties—have gained a great deal of scientific interest owing to their unique structure. Nanoparticle-based drugs are now widely regarded as a safer, more precise, and more effective mode of cancer therapy, considering their ability to enhance drug bioavailability, improve site-specific drug delivery, and protect nontarget tissues from toxic therapeutic drugs. This book compiles and details cutting-edge research in nanomedicine from an interdisciplinary team of international cancer researchers who are currently revolutionizing drug delivery techniques through the development of nanomedicines and nanotheranostics. Edited by Hala Gali-Muhtasib and Racha Chouaib, two prominent cancer researchers, this book will appeal to anyone involved in nanotechnology, cancer therapy, or drug delivery research.
Type: BOOK - Published: 2020-09-28 - Publisher: Springer Nature
This book summarizes the latest advances in nanomaterials and techniques in the field of tumor-targeted diagnosis and therapy. It provides valuable information for beginners and senior researchers, and stimulates new research directions by offering novel and provocative insights into the properties and technical principles of nanomaterials. The book systemically discusses the challenges in tumor treatment, current tumor-targeted strategies, drug-release strategies, diagnosis and therapeutic patterns, and also explores newly developed multifunctional nanomaterials and related systems.
Authors: Prashant Kesharwani, Kishore M. Paknikar, Virendra Gajbhiye
Type: BOOK - Published: 2019-07-08 - Publisher: Academic Press
Polymeric Nanoparticles as Promising Tool for Anti-cancer Therapeutics provides an understanding of polymeric compounds and their use in cancer therapies. The book begins by giving an overview of the current status, future challenges and potential utilization of polymeric nanoparticles. It then covers specific polymeric nanoparticles through contributions from world-renowned experts and researchers. Chapters examine specific polymeric nanoparticles, their development as potential targeted delivery systems, and cancer characteristics that can be targeted for therapy development. The book synthesizes current research trends in the field, thus enhancing existing knowledge of nanomedicine, drug delivery and therapeutic intervention strategies in human cancers. Users will find this to be an ideal reference for research scientists and those in the pharmaceutical and medical fields who are working to develop novel cancer therapies using nanoparticle-based delivery systems. Explores the development of polymeric nanoparticle systems for the purpose of cancer therapy Presents thoroughly analyzed data and results regarding the usage of polymeric nanoparticles-based platforms for the diagnosis and treatment of cancer Highlights various cancer characteristics that can be targeted for therapeutic development using polymeric nanoparticles
Type: BOOK - Published: 2014-10-15 - Publisher: Springer
This authoritative volume focuses on emerging technologies in cancer nano medicine, characterized by their multi-functionality and potential to address simultaneously diverse issues of clinical relevance in the treatment of cancer. The book consists of sixteen chapters divided into six sections: 1) Biological Barriers in Cancer; 2) Tumor Targeting; 3) Targeting the Immune System; 4) Gene Therapy; 5) Nano theranostics and 6) Translational Aspects of Nano-Oncologicals. The volume starts with an introduction describing the biological barriers associated with cancer therapy and highlighting ways to overcome such barriers through the use of nanotechnology. This is followed by an analysis of the two major targeting strategies currently under investigation in cancer therapy: namely, the targeting of cancer cells and the targeting of the immune system. In the first case, the book presents liposomal and polymer-based therapies, including photodynamic approaches. In the second case, it analyzes in detail the possibility of either improving the efficiency of the immune system toward preventing cancer progression (cancer immunomodulation) or generating responses against specific cancer antigens (cancer vaccines). Beyond these targeting options, Nano-Oncologicals: New Targeting and Delivery Approaches presents the most recent technological advances in the area of nucleic acid-based therapies, along with those in the area of theranostics, where the design of multifunctional nano carriers becomes vital. Following the study of the most promising nanotechnologies around the development of nano-oncologicals, the book ends with an overview of regulatory and toxicological issues, which are critical in their translational pathway, and the presentation of a nucleic acid-based therapy case-study. This book is an important resource for scientists interested in the design and development of anticancer nanotechnologies and also to those aiming to push their technology through clinical development.
Authors: Chad A. Mirkin, Thomas J. Meade, Sarah Hurst Petrosko, Alexander H. Stegh
Type: BOOK - Published: 2015-04-20 - Publisher: Springer
This book discusses emerging nanotechnology-based tools that have the potential to dramatically impact cancer research, diagnostics, and treatment. Cancer is a complex, devastating, and debilitating disease and, although much progress has been made, novel, more effective diagnostic and treatment options are still needed, especially for advanced cancers. The ultimate goal is to detect cancer early and non-invasively and to provide efficacious and targeted precision treatments that cause fewer harmful side effects. This book explains how nanotechnology can exploit the size-, shape-, and composition-dependent properties of nanomaterials to provide novel tools for precision cancer medicine. It will be of interest to researchers and professionals working in the fields of chemistry, biology, materials science and engineering, and medicine who want to learn more about this fascinating and fast-paced area of research.